Alnylam Pharmaceuticals, Inc. (ALNY)
Market Cap | 19.17B |
Revenue (ttm) | 1.83B |
Net Income (ttm) | -440.24M |
Shares Out | 125.95M |
EPS (ttm) | -3.52 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 554,941 |
Open | 154.48 |
Previous Close | 154.39 |
Day's Range | 149.28 - 154.50 |
52-Week Range | 143.52 - 218.88 |
Beta | 0.39 |
Analysts | Buy |
Price Target | 215.40 (+44.13%) |
Earnings Date | May 2, 2024 |
About ALNY
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the... [Read more]
Financial Performance
In 2023, ALNY's revenue was $1.83 billion, an increase of 76.23% compared to the previous year's $1.04 billion. Losses were -$440.24 million, -61.08% less than in 2022.
Financial StatementsAnalyst Forecast
According to 17 analysts, the average rating for ALNY stock is "Buy." The 12-month stock price forecast is $215.4, which is an increase of 44.13% from the latest price.
News
Levi & Korsinsky Announces an Investigation on Behalf of Alnylam Pharmaceuticals, Inc. (ALNY) Shareholders Who May Have Been Affected by Fraud
NEW YORK, NY / ACCESSWIRE / March 29, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ:ALNY) concerning possible v...
Investors who lost money on Alnylam Pharmaceuticals, Inc. should contact Levi & Korsinsky about an ongoing investigation - ALNY
NEW YORK, NY / ACCESSWIRE / March 28, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ:ALNY) concerning possible v...
Alnylam Being Investigated on Behalf of Alnylam Pharmaceuticals, Inc. Investors. Contact Levi & Korsinsky For Details.
NEW YORK, NY / ACCESSWIRE / March 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ:ALNY) concerning possible v...
Lost Money on Alnylam Pharmaceuticals, Inc.(ALNY)? Contact Levi & Korsinsky Regarding an Ongoing Investigation
NEW YORK, NY / ACCESSWIRE / March 25, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ:ALNY) concerning possible v...
Alnylam Pharmaceuticals, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details- ALNY
NEW YORK, NY / ACCESSWIRE / March 22, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ:ALNY) concerning possible v...
Did Alnylam Pharmaceuticals, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate- ALNY
NEW YORK, NY / ACCESSWIRE / March 21, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ:ALNY) concerning possible v...
Alnylam to Webcast Investor Event to Discuss Results from KARDIA-2 Phase 2 Study of Zilebesiran at American College of Cardiology Scientific Session
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will host a webcast event to discuss results from the KA...
ALNY ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your Alnylam Pharmaceuticals, Inc. Investment
NEW YORK, NY / ACCESSWIRE / March 20, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ:ALNY) concerning possible v...
ALNY STOCK ALERT: Levi & Korsinsky Notifies Alnylam Pharmaceuticals, Inc. Investors of an Ongoing Investigation
NEW YORK, NY / ACCESSWIRE / March 19, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ:ALNY) concerning possible v...
Alnylam Pharmaceuticals, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - ALNY
NEW YORK, NY / ACCESSWIRE / March 14, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ:ALNY) concerning possible v...
Alnylam Launches Hereditary ATTR (hATTR) Amyloidosis Campaign to Help Shorten Time to Diagnosis for Inherited and Rapidly Progressive Disease
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the launch of the Family Health History Road Trip, its program d...
ALNY ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Alnylam Pharmaceuticals, Inc.
NEW YORK, NY / ACCESSWIRE / March 13, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ:ALNY) concerning possible v...
Alnylam Pharmaceuticals, Inc. (ALNY) Shareholders May Have Been Affected by Fraud - Levi & Korsinsky Investigates
NEW YORK, NY / ACCESSWIRE / March 11, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ:ALNY) concerning possible v...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY
NEW YORK , March 11, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Alnylam Pharmaceuticals, Inc. ("Alnylam" or the "Company") (NASDAQ: ALNY). Such investors are...
Levi & Korsinsky Announces an Investigation on Behalf of Alnylam Pharmaceuticals, Inc. (ALNY) Shareholders Who May Have Been Affected by Fraud
NEW YORK, NY / ACCESSWIRE / March 11, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ:ALNY) concerning possible v...
Alnylam Pharmaceuticals, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - ALNY
NEW YORK, NY / ACCESSWIRE / March 7, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ:ALNY) concerning possible vi...
Alnylam Pharmaceuticals, Inc. (ALNY) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights
NEW YORK, NY / ACCESSWIRE / March 7, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ:ALNY) concerning possible vi...
Alnylam Pharmaceuticals, Inc. (ALNY) Shareholders May Have Been Affected by Fraud- Levi & Korsinsky, LLP Investigates
NEW YORK, NY / ACCESSWIRE / March 6, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ:ALNY) concerning possible vi...
Roche, Alnylam say blood pressure drug succeeds in mid-stage trial
Roche and partner Alnylam said on Tuesday their experimental drug against high blood pressure was shown to work when used in combination with the standard of care in a phase 2 trial.
Alnylam Pharmaceuticals, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Alnylam (ALNY)
NEW YORK, NY / ACCESSWIRE / March 5, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ:ALNY) concerning possible vi...
Alnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran is Added to Standard of Care Antihypertensives
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the KARDIA-2 Phase 2 study of zilebesiran, an investigation...
Levi & Korsinsky Reminds Shareholders of an Investigation into Alnylam Pharmaceuticals, Inc. (ALNY) Regarding Potential Securities Fraud Allegations
NEW YORK, NY / ACCESSWIRE / March 3, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ:ALNY) concerning possible vi...
Alnylam to Webcast Presentations at Upcoming March Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following ...
ALNY ALERT - Levi & Korsinsky Has Commenced an Investigation on Behalf of Alnylam Pharmaceuticals, Inc. Shareholders Who Lost Money
NEW YORK, NY / ACCESSWIRE / February 21, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ:ALNY) concerning possibl...
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Period Activity
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the fourth quarter and ful...